12 completed, 12 unknown, 3 terminated, 1 active not recruiting. 29 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 29 | Completed 12, Unknown 12, Terminated 3, Active not recruiting 1, Withdrawn 1 |
Follow Lymphoma, T-Cell: new trials by email Literature Review of Lymphoma, T-Cell trials Research Report on Lymphoma, T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Mogamulizumab - Cutaneous T-Cell Lymphoma | Phase 4 | Completed | Kyowa Kirin China Pharmaceutical Co., Ltd. | 23 | 2023-05-29 | 2026-09-09 |
| A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Brentuximab vedotin - T-Cell Lymphoma | Phase 4 | Completed | Takeda | 10 | 2022-11-28 | 2025-09-18 |
| Crizotinib Continuation Clinical Study crizotinib - NSCLC, ALCL | Phase 4 | Active not recruiting | Pfizer | 27 | 2021-12-27 | 2026-03-30 |
| A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum - Hemophagocytic Syndrome, T/NK-Cell Lymphoma | Phase 4 | Unknown | Zhengzhou University | 30 | 2021-05-30 | 2021-08-11 |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine - Peripheral T-cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 100 | 2019-09-01 | 2020-05-12 |
| PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma PD-1 Antibody, chidamide, lenalidomide and etoposide - NK/T Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 50 | 2019-04-01 | 2019-07-30 |
| Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Apatinib, CHOP Regimen - Newly Diagnosed Peripheral T-cell Lymphoma | Phase 4 | Unknown | Zhengzhou University | 100 | 2018-09-01 | 2018-08-15 |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas cisplatin, ifosfamide, gemcitabine - Peripheral T Cell Lymphoma | Phase 4 | Unknown | The University of Hong Kong | 50 | 2017-02-24 | 2018-06-11 |
| PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia rhG-CSF regimen, Pegylated rhG-CSF regimen - Lymphoma,Non-Hodgkin | Phase 4 | Unknown | Shandong Provincial Hospital | 240 | 2016-11-01 | 2016-12-19 |
| ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Anti-human Thymoglobulin, Placebo - Lymphoblastic Lymphoma | Phase 4 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 130 | 2016-10-01 | 2016-10-25 |
| A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Chidamide+ Etoposide - NK/T-Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 30 | 2016-10-01 | 2020-07-29 |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Pralatrexate - Peripheral T Cell Lymphoma, Progression, Disease | Phase 4 | Unknown | Taiwan Mundipharma Pharmaceuticals Ltd. | 22 | 2016-08-30 | 2017-05-12 |
| A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib crizotinib - Systemic Anaplastic Large-Cell Lymphoma | Phase 4 | Withdrawn | Jun Zhu | 2015-07-01 | 2016-12-30 | |
| Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Methotrexate, Interferon Alfa-2b - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides | Phase 4 | Terminated | Polish Lymphoma Research Group | 100 | 2014-06-01 | 2022-01-13 |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin - Hodgkin Lymphoma | Phase 4 | Completed | Millennium Pharmaceuticals, Inc. | 60 | 2014-03-14 | 2021-04-09 |
| Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Brentuximab vedotin - Lymphoma | Phase 4 | Completed | Takeda | 50 | 2014-01-23 | 2025-09-19 |
| CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified | Phase 4 | Unknown | Ruijin Hospital | 200 | 2012-09-01 | 2017-11-14 |
| Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Aprepitant, Placebo - Sezary Syndrome, Pruritus | Phase 4 | Terminated | Vanderbilt University Medical Center | 7 | 2012-02-01 | 2017-05-10 |
| Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma oral glucose tolerance test (OGTT) - Hypertriglyceridemia, Cutaneous T Cell Lymphoma | Phase 4 | Completed | Rennes University Hospital | 10 | 2012-01-01 | 2017-07-21 |
| Treatment of Peripheral T-cell Lymphoma GDPT regimen, CHOP regimen - Peripheral T-cell Lymphoma | Phase 4 | Completed | Mingzhi Zhang | 100 | 2011-08-01 | 2016-10-05 |
Showing 20 of 29. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (8) · Mycosis Fungoides (6) · Lymphoma, Extranodal NK-T-Cell (5) · Lymphoma, T-Cell, Peripheral (5) · Lymphoma, Large-Cell, Anaplastic (4) · Sezary Syndrome (3) · Hematologic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms (28) · Neoplasms by Histologic Type (28) · Lymphoma (27) · Lymphoma, Non-Hodgkin (27) · Hemic and Lymphatic Diseases (25) · Lymphatic Diseases (24) · Immune System Diseases (23) · Immunoproliferative Disorders (23) · Lymphoproliferative Disorders (23) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia (2)
Etoposide (5) · Gemcitabine (4) · Brentuximab Vedotin (3) · Cisplatin (3) · Dexamethasone (3) · Ifosfamide (3) · Methotrexate (3) · denileukin diftitox (3) · Crizotinib (2) · Cyclophosphamide (2) · Doxorubicin (2) · Lenalidomide (2) · Methoxsalen (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · VAP-cyclo protocol (2)
Mingzhi Zhang (6) · Eisai Inc. (3) · Takeda (2) · Zhengzhou University (2) · Bausch Health Americas, Inc. (1) · Jun Zhu (1) · Kyowa Kirin China Pharmaceutical Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Madrilenian Group of Cutaneous Lymphomas (1) · Millennium Pharmaceuticals, Inc. (1) · Nicola Goekbuget (1) · Pfizer (1) · Polish Lymphoma Research Group (1) · Rennes University Hospital (1) · Ruijin Hospital (1)
China (15) · United States (6) · Poland (5) · Germany (4) · Russia (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Canada (2) · Czechia (2) · Switzerland (2) · Taiwan (2) · Turkey (Türkiye) (2) · Belgium (1)
Mingzhi Zhang, Pro,Dr (3) · Elyane Lombardy, M.D. (2) · Bor-Sheng Ko, PhD (1) · Ewa Chmielowska, MD, PhD (1) · Francine Foss, M.D. (1) · Jun Zhu, MD (1) · Lei Zhang, Professor (1) · Madeleine Duvic, MD (1) · Mandeep Kaur, MD (1)
PMID 32632956, PMID 23770157, PMID 11863096, PMID 14585365, PMID 17410187, PMID 18626005, PMID 19167677, PMID 21575927, PMID 22677206, PMID 23383989, PMID 25359988, PMID 25559471, PMID 26230956, PMID 27060152, PMID 27384676, PMID 28597542, PMID 30140912, PMID 31118779, PMID 32550864, PMID 33034052, PMID 35708709, PMID 7581076